Geode Capital Management’s Lyra Therapeutics LYRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $98.5K | Sell |
10,986
-9,334
| -46% | -$83.6K | ﹤0.01% | 4064 |
|
|
2025
Q1 | $128K | Buy |
20,320
+2,601
| +15% | +$16.4K | ﹤0.01% | 3964 |
|
|
2024
Q4 | $183K | Buy |
17,719
+2,351
| +15% | +$24.3K | ﹤0.01% | 3931 |
|
|
2024
Q3 | $198K | Buy |
15,368
+266
| +2% | +$3.42K | ﹤0.01% | 3906 |
|
|
2024
Q2 | $209K | Buy |
15,102
+7,913
| +110% | +$109K | ﹤0.01% | 3891 |
|
|
2024
Q1 | $2.24M | Buy |
7,189
+460
| +7% | +$143K | ﹤0.01% | 3072 |
|
|
2023
Q4 | $1.76M | Buy |
6,729
+555
| +9% | +$145K | ﹤0.01% | 3153 |
|
|
2023
Q3 | $1.21M | Buy |
6,174
+3,197
| +107% | +$625K | ﹤0.01% | 3248 |
|
|
2023
Q2 | $612K | Hold |
2,977
| – | – | ﹤0.01% | 3566 |
|
|
2023
Q1 | $308K | Hold |
2,977
| – | – | ﹤0.01% | 3849 |
|
|
2022
Q4 | $467K | Buy |
2,977
+40
| +1% | +$6.28K | ﹤0.01% | 3689 |
|
|
2022
Q3 | $735K | Buy |
2,937
+527
| +22% | +$132K | ﹤0.01% | 3540 |
|
|
2022
Q2 | $680K | Buy |
2,410
+1,661
| +222% | +$469K | ﹤0.01% | 3589 |
|
|
2022
Q1 | $150K | Buy |
749
+29
| +4% | +$5.81K | ﹤0.01% | 4507 |
|
|
2021
Q4 | $157K | Hold |
720
| – | – | ﹤0.01% | 4578 |
|
|
2021
Q3 | $329K | Sell |
720
-2
| -0.3% | -$914 | ﹤0.01% | 4223 |
|
|
2021
Q2 | $289K | Sell |
722
-1,084
| -60% | -$434K | ﹤0.01% | 4183 |
|
|
2021
Q1 | $1.05M | Buy |
1,806
+436
| +32% | +$253K | ﹤0.01% | 3540 |
|
|
2020
Q4 | $781K | Buy |
1,370
+560
| +69% | +$319K | ﹤0.01% | 3443 |
|
|
2020
Q3 | $452K | Buy |
810
+147
| +22% | +$82K | ﹤0.01% | 3454 |
|
|
2020
Q2 | $375K | Buy |
+663
| New | +$375K | ﹤0.01% | 3469 |
|